• Criptomoedas
  • Mercados de Previsão
  • Notícias
  • Trading Agêntico
  • Artigos
  • Ligas

Pesquisar Criptomoedas

Criptomoedas em tendência

CoinRithm

Empresa

Entidade legal
Bees-x Limited
Número da empresa
13308136
Constituída em
England and Wales
Sede registrada
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm é um serviço de informação e pesquisa operado pela Bees-x Limited. Não é autorizado pela Financial Conduct Authority (FCA) a realizar atividades reguladas, e nada neste site constitui aconselhamento financeiro.

Explorar

CriptomoedasMercados de PrevisãoNotíciasArtigosAgent ArenaLigas

Recursos

Painel de ControleComércio SimuladoTrading AgênticoCarteiraLista de ObservaçãoConfigurações

Empresa

Sobre NósMetodologiaPara salas de aulaTermos de UsoPolítica de PrivacidadePolítica de CookiesAviso Legal

Suporte

Apoio ao ClienteFAQKit para desenvolvedoresDocumentação MCP

Redes Sociais

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Direitos reservados.
Disponível no Google PlayBaixar na App Store
  • Início
  • MercadosMercados de Previsão
  • Notícias
  • Painel de Controle
  1. Mercados de Previsão
  2. Regulamentação
  3. FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)

FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)

RegulamentaçãoOne-OffHealth & Medicine6m
KalshiKalshiVerificar disponibilidadeKYC obrigatório2% de taxa
Probabilidade implícita atual
Sim
Sim 0%
Qualidade do mercado

24 / 100

Baixa qualidade
Volume 24h

0 €

Liquidez

0 €

Baixa liquidez
Compra / Venda

67.0% / 74.0%

Spread

10.4%

Spread amplo
Dados do mercado

Atualizado há 4 minutos

17/06/26, 21:301/01/27, 4:59

Tendências

Resultado24hProbabilidade
Sim
Sim
0%
Não
Não
100%

Resultado escolhido

Yes0%

Regras

If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

Kalshi
  • This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
  • Saroglitazar (sold under the brand name Lipaglyn in India) is an oral small-molecule drug developed by Zydus Therapeutics that is designed to simultaneously activate two molecular switches in the body — called PPAR-alpha and PPAR-gamma — which together regulate how the body handles fats and sugars.
  • Think of it like a dual-dial thermostat for metabolism: turning up both dials at once aims to reduce harmful lipid buildup and improve insulin sensitivity more effectively than nudging just one dial.
  • In the EPICS-III trial , it is being evaluated as a treatment for primary biliary cholangitis, a liver disease distinct from its original metabolic indications.

Mercados Relacionados

Manifold Markets

Testosterone unscheduled/rescheduled more permissively in US by end of 2028?

994,7 €
Sim: 22.2%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Will China have more phase 3 drug trials than the United States in year X?

367,9 €
2026: 33%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Will estradiol be available over-the-counter in the US before 2030?

303 €
Sim: 8.2%Manifold MarketsMANIFOLD MARKETS
FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026)

FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026)

0 €
Sim: 0%KalshiKALSHI
Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

38,2 mil €
Sim: 4%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

5,2 mil €
Sim: 11%PolymarketPOLYMARKET

Ativos nestes tópicos

BitcoinBTC$64,629.89-1.78%EthereumETH$1,757.30-2.12%SolanaSOL$72.45-1.60%DogecoinDOGE$0.0864-1.25%XRPXRP$1.19-2.24%BNBBNB$603.36-0.41%

Notícias Relacionadas

Binance MiCA License Application Cleared by Greek Regulator, June 30 Update AwaitedBlockchain ReporterCLARITY Act faces ethics showdown as David Nage eyes July voteCrypto NewsBinance EU Access at Risk as Greek Regulator Set to Reject MiCA License BidBlockchain ReporterSolana Institute warns Senate against weakening CLARITY ActCrypto NewsSummer of crypto (regs): State of Crypto CoindeskPhilippine Central Bank Bars VASPs From Listing Privacy CoinsBlockchain Reporter

Regras

If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

Kalshi
  • This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
  • Saroglitazar (sold under the brand name Lipaglyn in India) is an oral small-molecule drug developed by Zydus Therapeutics that is designed to simultaneously activate two molecular switches in the body — called PPAR-alpha and PPAR-gamma — which together regulate how the body handles fats and sugars.
  • Think of it like a dual-dial thermostat for metabolism: turning up both dials at once aims to reduce harmful lipid buildup and improve insulin sensitivity more effectively than nudging just one dial.
  • In the EPICS-III trial , it is being evaluated as a treatment for primary biliary cholangitis, a liver disease distinct from its original metabolic indications.